SECAUCUS, N.J., Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m. Eastern Time.The fireside chat and Q&A session will be webcast live ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-12215 Quest Diagnostics Incorporated 500 Plaza Drive Secaucus, NJ 07094 (973) 520-2700 Delaware 16-1387862 ...

Quest Diagnostics (DGX) recently introduced a highly advanced predictive gene expression test, MelaNodal Predict, to help personalize treatment decisions for patients with melanoma.  The lab-developed test is based on the technology developed by the biotechnology company, SkylineDx, alongside Mayo Clinic and has been validated by DGX.The latest development will strongly fortify the company’s oncology test offering across the advanced diagnostics spectrum. Dermatologists and other providers nationwide can be ...

–  Roche led the financing alongside existing and new investors –  – The funds will progress clinical programs and expand platform capabilities – SOUTH SAN FRANCISCO, Calif., Feb. 15, 2024 /PRNewswire/ -- Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors. The funding enables Freenome to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platfor ...

Quest Diagnostics (DGX) recently introduced its first consumer-initiated blood-draw test for PFAS (Per- and Polyfluorinated alkyl substances, also known as "forever chemicals") on questhealth.com. In contrast to traditional direct-to-consumer tests, the new test involves physician oversight and consultation on request with a licensed physician.The PFAS (Forever Chemicals) Test Panel is also widely available, with individuals having the option to visit most of DGX’s approximately 2,100 patient service center ...

The fourth-quarter reporting cycle is in full swing. The MedTech companies (Zacks-defined Medical Products stocks) within the broader Medical sector have witnessed a year-over-year deterioration in earnings.The MedTech stocks that have released their earnings so far showed market share gain within their base businesses through the months of the fourth quarter compared with the same period in 2022. However, ongoing macroeconomic headwinds in the form of inflation and labordemics put pressure on the bottom li ...

Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to have survival rate of over 90 percent  SECAUCUS, N.J., and SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize ...

Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations interested in workforce, community, and research population testing may also access the test SECAUCUS, N.J., Feb. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leader in diagnostic information services, today announced the availability of the first consumer-initiated, physician-ordered blood- ...

AzmanJaka Investment Thesis Quest Diagnostics (NYSE:DGX) is an exceptionally stable company that operates a fantastic business. Over the last 10 years, its total return has exceeded that of the S&P500, and in the last 20 years, its shares have never fallen by more than 36%, even during the crises of 2008 and 2020. This fact underscores the resilience and strength of the business. However, in 2020, the company benefited from COVID-19 testing, which atypically boosted growth and margins, leading to an ove ...

Quest Diagnostics Inc. (NYSE:DGX) Q4 2023 Results Conference Call February 1, 2024 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer and President Sam Samad - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Pito Chickering - Deutsche Bank. Jack Meehan - Nephron Research Brian Tanquilut - Jefferies Andrea Alfonso - UBS Lisa Gill - JPMorgan Derik de Bruin - Bank of Amer ...